Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$29.00K$29.00Kderived−98.1% vs Q4 2019 Net Income-$3.15M-$3.15MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$16,000−40.7% Operating Incomederived-$2,443,000N/M Operating Cash Flowderived-$1,993,000N/M Free Cash Flowderived-$2,707,000N/M Margins · derivedGross margin55.2%+53.4 pt vs Q4 2019
Operating margin-8424.1%−8314.0 pt vs Q4 2019
Net margin-10875.9%−10773.5 pt vs Q4 2019
ended Mar 31, 2020 · filed Jul 13, 2020 · 104 d after period end